MERIT MEDICAL SYSTEMS INC (MMSI) Stock
1 member of Congress disclosed 2 trades in MMSI since 2025: 1 purchase and 1 sale, most recently Lisa McClain (sale, Sep 25, 2025). 7 of the hedge funds AlphaScala tracks reported MMSI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Maverick Capital's at $67.86M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Nov 3, 2026.
Which members of Congress traded MERIT MEDICAL SYSTEMS INC (MMSI)?
Most recent: Lisa McClain (sale, Sep 25, 2025); records start Jul 22, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-09-25 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-07-22 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all MMSI political trades →Which hedge funds own MMSI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Maverick Capital Lee Ainslie | 979K | $67.86M | +37% |
| Citadel Ken Griffin | 910K | $63.09M | -6% |
| Marshall Wace | 349K | $24.21M | -39% |
| Point72 Steve Cohen | 204K | $14.13M | -73% |
| D.E. Shaw David Shaw | 190K | $13.15M | +41% |
| Renaissance Technologies Jim Simons (founder) | 125K | $8.70M | -60% |
| Bridgewater Associates Ray Dalio | 35K | $2.45M | +542% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are MERIT MEDICAL SYSTEMS INC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 24, 26 | Peterson Neil W. | CHIEF OPERATING OFFICER | SELL | 7.5K | $678K |
| Aug 4, 26 | Peterson Neil W. | CHIEF OPERATING OFFICER | SELL | 21.4K | $1.8M |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →MMSI price chart
Powered by TradingViewWhat does MERIT MEDICAL SYSTEMS INC do?
Merit Medical Systems, Inc. is a medical device company that designs, develops, manufactures, and markets specialized disposable products for interventional and diagnostic procedures worldwide. It operates through two primary segments: Cardiovascular and Endoscopy. The Cardiovascular segment provides cardiology and radiology devices for diagnosing and treating coronary arterial disease, peripheral vascular disease, and other non-vascular conditions, including embolotherapeutic products, cardiac rhythm management tools, electrophysiology devices, critical care monitors, breast cancer localization systems, biopsy instruments, interventional oncology solutions, and spine devices. The Endoscopy segment offers gastroenterology and pulmonology products such as stents and balloon dilators for palliative treatment of esophageal, tracheobronchial, and biliary strictures caused by malignant tumors. Within these segments, Merit Medical Systems delivers peripheral intervention tools like drainage catheters and microcatheters, cardiac intervention items including introducer sheaths and guide wires, custom procedural solutions, original equipment manufacturer components, and endoscopy devices. The company sells directly to hospitals and physicians in the United States and through distributors internationally, maintaining a global presence across North America, Europe, the Middle East, Africa, Asia, and Latin America. Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical Systems supports healthcare professionals in vascular access, diagnostics, treatments, and patient monitoring with its portfolio of over 1,700 patented products.